Effect of an Antioxidant Dietary Supplement on Skin Radiance

Randomized Double-Blind Placebo-Controlled Trial Evaluating the Effect of an Oral Antioxidant Dietary Supplement on Skin Radiance in Women Exposed to Urban Air Pollution

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07793123

Enrollment

Registered

2026-08-28

Start date

2026-09-01

Completion date

2026-12-01

Last updated

2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Women

Keywords

Skin, pollution, Radiance

Brief summary

A randomized, double-blind, placebo-controlled study evaluating the effects of an oral antioxidant dietary supplement on skin radiance in women exposed to urban air pollution. Secondary assessments include skin tone homogeneity, pigmentation, inflammation, skin barrier function, glycation markers.

Interventions

DIETARY_SUPPLEMENTAntioxidant Supplement

Oral antioxidant dietary supplement administered as one capsule once daily for 90 days.

DIETARY_SUPPLEMENTPlacebo

Placebo dietary supplement administered as one capsule once daily for 90 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

35 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy female aged 35 to 65 years * Fitzpatrick skin phototype II to IV * All skin types * Dull and uneven skin tone * Living in an urban environment and exposed to air pollution * Able to comply with study procedures * Written informed consent provided

Exclusion criteria

* Pregnant or breastfeeding * Current use of dietary supplements or vitamin supplements * Specific dietary restrictions * Unstable medication affecting water retention * Active medical disease * Facial dermatological disorder * Participation in another clinical trial * Vulnerable populations according to French regulations

Design outcomes

Primary

Measure	Time frame	Description
Skin Radiance	Day 0 and Day 90	Glossymeter

Secondary

Measure	Time frame	Description
Skin Radiance	Day 0 and Day 30	Glossymeter
Skin homogeneity	Day 0, Day 30, Day 90	VISIA CR5
TransEpidermal Water Loss	Day 0, Day 30, Day 90	Tewameter
Skin glycation	Day 0, Day 30, Day 90	AGEscanner
skin IL8	Day 0, Day 30, Day 90	IL8 assay

Countries

France

Contacts

CONTACTAudrey Gauthier

audrey.gauthier@robertet.com+33 484 85 96 82

CONTACTPascale Berthon

pascale.berthon@robertet.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026